Concepedia

Author

Richard Czerniak

Takeda (United States)

Also Known As

R Czerniak, R. CZERNIAK, R. Czerniak, Richard Czerniak

25

Publications

685

Citations

10

H-Index

23

Concepts

All Affiliations

Takeda (United States)Takeda (Japan)Institute for Cancer Prevention
RC

About

Richard Czerniak is an author at Takeda (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

166

2

Biochemistry

3

3

149

3

Metabolism

2

2

128

4

Natural Sciences

1

1

21

5

Hepatology

1

1

104

Richard Czerniak

×

7

Publications

273

Citations

7

H-Index

YearCitations

Picornavirus Inhibitors: Trifluoromethyl Substitution Provides a Global Protective Effect against Hepatic Metabolism

Guy D. Diana, Patrick J. Rudewicz, Daniel C. Pevear,

Journal of Medicinal Chemistry

1995

104

Assay of 1-nitropropane, 2-nitropropane, 1-azoxypropane and 2-azoxypropane for carcinogenicity by gavage in Sprague—Dawley rats

Emerich S. Fiala, Richard Czerniak, André Castonguay,

Carcinogenesis

1987

79

Differential effects of 4-iodopyrazole and 3-methylpyrazole on the metabolic activation of methylazoxymethanol to a DNA methylating species by rat liver and rat colon mucosa in vivo

Emerich S. Fiala, Ock Soon Sohn, Christine Puz,

Journal of Cancer Research and Clinical Oncology

1987

24

Natural quinones as quinonemethide precursors--ideas in rational drug design.

Moore Hw, Richard Czerniak, Ahmed M. Hamdan

PubMed

1986

21

Randomized clinical trial: A double‐blind, proof‐of‐concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro‐esophageal reflux disease and partial response to a healing dose of a proton‐pump inhibitor

Jan Tack, Borislav Vladimirov, Ivo Horný,

Neurogastroenterology & Motility

2022

18

In Vitro Assessment of Potential for CYP-Inhibition-Based Drug–Drug Interaction Between Vonoprazan and Clopidogrel

Mitsuhiro Nishihara, Hitomi Yamasaki, Richard Czerniak,

European Journal of Drug Metabolism and Pharmacokinetics

2018

17

Pharmacokinetics, Safety, and Tolerability of Vonoprazan‐ or Esomeprazole‐Based Bismuth‐Containing Quadruple Therapy: A Phase 1, Double‐Blind, Parallel‐Group Study in Adults with <i>Helicobacter pylori</i> Infection in China

Jia Miao, Chao Hu, Jie Tang,

Clinical Pharmacology in Drug Development

2023

10

Page 1